GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » Net Issuance of Debt

Innovative Pharmaceutical Biotech (HKSE:00399) Net Issuance of Debt : HK$18.18 Mil (TTM As of Sep. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Innovative Pharmaceutical Biotech's net issuance of debt for the six months ended in Sep. 2023 was HK$4.80 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Sep. 2023 was HK$18.18 Mil.

Innovative Pharmaceutical Biotech Net Issuance of Debt Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech Net Issuance of Debt Chart

Innovative Pharmaceutical Biotech Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.48 -8.20 13.00 20.00 16.88

Innovative Pharmaceutical Biotech Semi-Annual Data
Dec13 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.00 10.00 3.50 13.38 4.80

Innovative Pharmaceutical Biotech Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$18.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovative Pharmaceutical Biotech Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative Pharmaceutical Biotech (HKSE:00399) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » Net Issuance of Debt
Comparable Companies
HKSE:06893 HKSE:01667 HKSE:01962 HKSE:08512 HKSE:00464 HKSE:02023 HKSE:08176 HKSE:03332 HKSE:01455 HKSE:02031 PG XPAR:OR LSE:ULVR CL BOM:500696 EL KMB LSE:RKT KVUE XTER:BEI
Traded in Other Exchanges
N/A
Address
168-200 Connaught Road Central, Unit No. 2111, 21st Floor, Sheung Wan, West Tower Shun Tak Centre, Hong Kong, HKG
Website
http://www.ipb.asia
Innovative Pharmaceutical Biotech Ltd is focused on developing an insulin product that could be administered orally. It has two primary segments of business: the research and development of pharmaceutical products and the trading of beauty products. It generates maximum revenue from trading in the beauty products segment.

Innovative Pharmaceutical Biotech (HKSE:00399) Headlines

No Headlines